Alfred D Kingsley Oncocyte Corp (OCX) insider trading activity

Alfred D Kingsley is Director of Oncocyte Corp. Currently has a direct ownership of 489,111 shares of OCX, which is worth approximately $1.26 Million. The most recent transaction as insider was on Jun 23, 2023, when has been sold 20,000 shares (Common Stock, No Par Value) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 489K

0% 3M change

0% 12M change

Total Value Held $1.26 Million

ALFRED D KINGSLEY Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jun 23 2023	BUY Grant, award, or other acquisition	-	20,000 Added 3.93%	489,111 Common Stock, No Par V...
Jun 14 2023	BUY Open market or private purchase	$6,300 $0.21 p/Share	30,000 Added 6.01%	469,111 Common Stock, No Par V...
Dec 22 2022	BUY Open market or private purchase	$7,000 $0.28 p/Share	25,000 Added 5.39%	439,111 Common Stock, No Par V...
Aug 15 2022	BUY Open market or private purchase	$9,700 $0.97 p/Share	10,000 Added 2.36%	414,111 Common Stock, No Par V...
Aug 15 2022	BUY Grant, award, or other acquisition	-	10,000 Added 2.41%	404,111 Common Stock, No Par V...
Jun 24 2022	BUY Exercise of conversion of derivative security	-	10,000 Added 2.47%	394,111 Common Stock, No Par V...
Dec 28 2020	BUY Exercise of conversion of derivative security	$87,463 $1.34 p/Share	65,271 Added 14.52%	384,111 Common Stock, No Par V...
Dec 23 2020	SELL Open market or private sale	$2,295 $2.55 p/Share	900 Reduced 0.28%	318,840 Common Stock, No Par V...
Dec 23 2020	BUY Exercise of conversion of derivative security	$1,658 $1.34 p/Share	1,237 Added 0.39%	319,740 Common Stock, No Par V...
Dec 22 2020	SELL Open market or private sale	-	7,652 Reduced 2.35%	318,503 Common Stock, No Par V...
Dec 22 2020	BUY Exercise of conversion of derivative security	$14,091 $1.34 p/Share	10,516 Added 3.12%	326,155 Common Stock, No Par V...
Dec 21 2020	SELL Open market or private sale	$89,276 $2.54 p/Share	35,148 Reduced 10.02%	315,639 Common Stock, No Par V...
Dec 21 2020	BUY Exercise of conversion of derivative security	$64,288 $1.34 p/Share	47,976 Added 12.03%	350,787 Common Stock, No Par V...
Dec 11 2020	BUY Grant, award, or other acquisition	-	5,909 Added 1.91%	302,811 Common Stock

Also insider at

LCTX

Lineage Cell Therapeutics, Inc. Healthcare

Chairman

ADK